BrainStorm (BCLI) Cell Therapeutics announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through June 30 to regain compliance with certain continued listing standards of The Nasdaq Capital Market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks